The further elucidation of this regulatory mechanism, particularly the identification of the responsible 2-OGDD(s), could thus lead to the establishment of new therapeutic strategies to overcome the chemotherapy resistance of hypoxic cancer cells by inhibiting ATAD2 proteolysis under hypoxic conditions and restoring cell cycle delay (Figure 5). This evidence concerns the gene ATAD2 and cancer.